BRIEF-Revive to start Phase 2b trial in gout after access to required capital
May 10 (Reuters) - Revive Therapeutics Ltd
* Says will start its Phase 2B trial in gout when it has access to capital necessary to fund trial
* Over last several months, has taken necessary steps to reduce its monthly cash burn rate and streamline its operations Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
© Thomson Reuters 2017 All rights reserved.